JP2010526543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526543A5 JP2010526543A5 JP2010507770A JP2010507770A JP2010526543A5 JP 2010526543 A5 JP2010526543 A5 JP 2010526543A5 JP 2010507770 A JP2010507770 A JP 2010507770A JP 2010507770 A JP2010507770 A JP 2010507770A JP 2010526543 A5 JP2010526543 A5 JP 2010526543A5
- Authority
- JP
- Japan
- Prior art keywords
- alkaline phosphatase
- amino acid
- seq
- cell
- salp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 36
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 36
- 125000000539 amino acid group Chemical group 0.000 claims 13
- 150000001413 amino acids Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 230000033558 biomineral tissue development Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010058314 Dysplasia Diseases 0.000 claims 3
- 229920000805 Polyaspartic acid Polymers 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010064470 polyaspartate Proteins 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- KJBQDYDTQCIAFO-ZLELNMGESA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group CC(C)C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O KJBQDYDTQCIAFO-ZLELNMGESA-N 0.000 claims 2
- SEFLNGWGXSFZMH-DQZFIDPSSA-N (2s)-2-aminobutanedioic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical group CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(O)=O SEFLNGWGXSFZMH-DQZFIDPSSA-N 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 2
- 230000018678 bone mineralization Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000029663 Hypophosphatemia Diseases 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 210000001750 dental cementum Anatomy 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001872 metatarsal bone Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000002303 tibia Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758907P | 2007-05-11 | 2007-05-11 | |
| US60/917,589 | 2007-05-11 | ||
| PCT/CA2008/000923 WO2008138131A1 (en) | 2007-05-11 | 2008-05-12 | Bone targeted alkaline phosphatase, kits and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526543A JP2010526543A (ja) | 2010-08-05 |
| JP2010526543A5 true JP2010526543A5 (https=) | 2011-06-30 |
| JP5732603B2 JP5732603B2 (ja) | 2015-06-10 |
Family
ID=40001639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507770A Active JP5732603B2 (ja) | 2007-05-11 | 2008-05-12 | 骨標的アルカリホスファターゼ、キット及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20100297119A1 (https=) |
| EP (3) | EP2158319B1 (https=) |
| JP (1) | JP5732603B2 (https=) |
| AT (1) | ATE536413T1 (https=) |
| AU (1) | AU2008250945B2 (https=) |
| BR (2) | BR122019000505B1 (https=) |
| CA (1) | CA2687001C (https=) |
| CY (1) | CY2016005I1 (https=) |
| DE (1) | DE202008018131U1 (https=) |
| DK (3) | DK2158319T3 (https=) |
| ES (3) | ES2471915T3 (https=) |
| FR (1) | FR16C0007I2 (https=) |
| HR (1) | HRP20140416T1 (https=) |
| HU (2) | HUE031655T2 (https=) |
| IL (1) | IL202057A0 (https=) |
| LT (1) | LTC2368999I2 (https=) |
| LU (1) | LU92976I2 (https=) |
| ME (1) | ME01828B (https=) |
| NL (1) | NL300798I2 (https=) |
| NO (1) | NO2016002I1 (https=) |
| PL (3) | PL2662448T3 (https=) |
| PT (3) | PT2662448T (https=) |
| RS (1) | RS53302B (https=) |
| SI (2) | SI2368999T1 (https=) |
| WO (1) | WO2008138131A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005027461D1 (de) | 2004-04-21 | 2011-05-26 | Enobia Pharma Inc | Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| US8784833B2 (en) * | 2006-06-27 | 2014-07-22 | Saint Louis University | Prenatal enzyme replacement therapy for hypophosphatasia |
| CN101835802B (zh) | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| ES2628841T3 (es) | 2010-03-12 | 2017-08-04 | Alexion Pharmaceuticals, Inc. | Proteínas de fusión npp1 |
| BR112012027765A2 (pt) | 2010-04-30 | 2019-09-24 | Enobia Pharma Inc. | métodos, composições e kits para tratamento de distúrbios de mineralização da matriz. |
| WO2012016073A2 (en) | 2010-07-28 | 2012-02-02 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| CA2852874A1 (en) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| JP2015527366A (ja) | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| US9926544B2 (en) * | 2014-01-24 | 2018-03-27 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
| US10822596B2 (en) * | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| LT3325011T (lt) | 2015-07-24 | 2021-01-25 | Gliknik Inc. | Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu |
| JP6993961B2 (ja) * | 2015-08-17 | 2022-01-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼの製造 |
| EP3355904A4 (en) * | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| WO2017155569A1 (en) * | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| WO2017171871A1 (en) * | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| KR20240160671A (ko) | 2016-04-01 | 2024-11-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
| EP3464573B1 (en) | 2016-06-06 | 2026-03-04 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| WO2017214321A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| WO2018004517A1 (en) | 2016-06-27 | 2018-01-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children and adolescents |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| WO2018102616A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| CN110177802A (zh) | 2016-12-09 | 2019-08-27 | 格利克尼克股份有限公司 | 多聚化stradomer GL-2045的制造优化 |
| CA3043251A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| WO2018164995A1 (en) * | 2017-03-09 | 2018-09-13 | Alexion Pharmaceuticals, Inc . | Glycoprotein manufacturing process |
| KR20190129058A (ko) * | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
| EP3687565A1 (en) | 2017-09-27 | 2020-08-05 | Alexion Pharmaceuticals, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
| CA3087569A1 (en) | 2018-01-09 | 2019-07-18 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| JP7214962B2 (ja) * | 2018-01-17 | 2023-01-31 | 東ソー株式会社 | アルカリホスファターゼ高発現動物細胞 |
| WO2019183208A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| EP4275761A3 (en) | 2018-03-20 | 2024-02-28 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| CN110499284A (zh) * | 2018-05-17 | 2019-11-26 | 西安组织工程与再生医学研究所 | Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用 |
| WO2019232285A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| ES2972119T3 (es) | 2018-08-10 | 2024-06-11 | Alexion Pharma Inc | Cicatrización ósea en implantes utilizando fosfatasa alcalina |
| KR20220005560A (ko) | 2019-05-06 | 2022-01-13 | 신세틱 바이오로직스, 인코퍼레이티드 | 알칼리성 포스페이트-기반 종양학 치료제 |
| KR20220111693A (ko) * | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법 |
| EP4084819A1 (en) | 2020-01-03 | 2022-11-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Tnap locally administered for promoting periodontal health |
| AU2021338361A1 (en) * | 2020-09-03 | 2023-04-06 | Chen, Irvin S.Y | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| KR102571967B1 (ko) * | 2021-01-21 | 2023-08-30 | 주식회사 마라나노텍코리아 | Alp 측정용 바이오 센서 |
| US12083169B2 (en) * | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| US20260027233A1 (en) * | 2022-08-31 | 2026-01-29 | University Of Utah Research Foundation | Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7008A (en) * | 1850-01-08 | Improvement in alloys for points of lightning-rods | ||
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| ATE437221T1 (de) | 2001-05-14 | 2009-08-15 | Gbp Ip Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
| CA2433479A1 (en) | 2002-07-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof |
| DE602005027461D1 (de) | 2004-04-21 | 2011-05-26 | Enobia Pharma Inc | Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| EP1781318A4 (en) | 2004-06-23 | 2009-12-23 | Genzyme Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES |
| US20090142347A1 (en) * | 2004-09-29 | 2009-06-04 | The Burnham Institute For Medical Research | Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification |
| CN101068575A (zh) | 2004-12-01 | 2007-11-07 | 建新公司 | 向肝脏定向递送遗传物质的方法 |
-
2008
- 2008-05-12 PT PT130023278T patent/PT2662448T/pt unknown
- 2008-05-12 AU AU2008250945A patent/AU2008250945B2/en active Active
- 2008-05-12 RS RS20140237A patent/RS53302B/sr unknown
- 2008-05-12 PT PT08757088T patent/PT2158319E/pt unknown
- 2008-05-12 WO PCT/CA2008/000923 patent/WO2008138131A1/en not_active Ceased
- 2008-05-12 JP JP2010507770A patent/JP5732603B2/ja active Active
- 2008-05-12 DK DK08757088.3T patent/DK2158319T3/da active
- 2008-05-12 SI SI200831200T patent/SI2368999T1/sl unknown
- 2008-05-12 US US12/599,679 patent/US20100297119A1/en not_active Abandoned
- 2008-05-12 BR BR122019000505-2A patent/BR122019000505B1/pt active Search and Examination
- 2008-05-12 BR BRPI0811198A patent/BRPI0811198B8/pt active IP Right Grant
- 2008-05-12 EP EP08757088A patent/EP2158319B1/en active Active
- 2008-05-12 PL PL13002327T patent/PL2662448T3/pl unknown
- 2008-05-12 ES ES11004496.3T patent/ES2471915T3/es active Active
- 2008-05-12 ES ES13002327T patent/ES2619332T3/es active Active
- 2008-05-12 HU HUE13002327A patent/HUE031655T2/hu unknown
- 2008-05-12 ME MEP-2014-48A patent/ME01828B/me unknown
- 2008-05-12 SI SI200831780A patent/SI2662448T1/sl unknown
- 2008-05-12 EP EP13002327.8A patent/EP2662448B1/en active Active
- 2008-05-12 PT PT110044963T patent/PT2368999E/pt unknown
- 2008-05-12 DE DE202008018131U patent/DE202008018131U1/de not_active Expired - Lifetime
- 2008-05-12 PL PL11004496T patent/PL2368999T3/pl unknown
- 2008-05-12 EP EP11004496.3A patent/EP2368999B1/en active Active
- 2008-05-12 DK DK13002327.8T patent/DK2662448T3/en active
- 2008-05-12 PL PL08757088T patent/PL2158319T4/pl unknown
- 2008-05-12 AT AT08757088T patent/ATE536413T1/de active
- 2008-05-12 CA CA2687001A patent/CA2687001C/en active Active
- 2008-05-12 ES ES08757088T patent/ES2380546T3/es active Active
- 2008-05-12 DK DK11004496.3T patent/DK2368999T3/da active
-
2009
- 2009-11-11 IL IL202057A patent/IL202057A0/en unknown
-
2014
- 2014-05-08 HR HRP20140416AT patent/HRP20140416T1/hr unknown
-
2016
- 2016-01-15 HU HUS1600005C patent/HUS1600005I1/hu unknown
- 2016-01-28 LT LTPA2016004C patent/LTC2368999I2/lt unknown
- 2016-02-02 NO NO2016002C patent/NO2016002I1/no not_active IP Right Cessation
- 2016-02-10 LU LU92976C patent/LU92976I2/xx unknown
- 2016-02-19 FR FR16C0007C patent/FR16C0007I2/fr active Active
- 2016-02-23 CY CY2016005C patent/CY2016005I1/el unknown
- 2016-02-26 NL NL300798C patent/NL300798I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526543A5 (https=) | ||
| HRP20140416T1 (hr) | Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe | |
| JP6542433B2 (ja) | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 | |
| US9527901B2 (en) | Recombinant bi-functional fusion proteins, preparations and methods for treating disease | |
| KR102651018B1 (ko) | 점도저하제를 함유하는 액체 단백질 제형 | |
| EP3287470B1 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
| ES2674888T3 (es) | Anticuerpos para OPGL | |
| ES2579906T3 (es) | Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas | |
| TWI705822B (zh) | 包含纖維蛋白溶酶原之醫藥組合物及其用途 | |
| BR112020026862A2 (pt) | antagonistas antitumorais de reguladores de pontos de verificação imunológica | |
| TW201200152A (en) | Novel antibody formulation | |
| KR102928496B1 (ko) | 돌연변이된 절단된 폰 빌레브란트 인자 | |
| BRPI0710508B1 (pt) | composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído | |
| KR20140084208A (ko) | 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법 | |
| EA014232B1 (ru) | Стабильные белковые препараты | |
| TW201021826A (en) | Stabilized receptor polypeptides and uses thereof | |
| ES2981475T3 (es) | Composiciones selectivas de inhibidor de la señalización IL-6-trans | |
| CA2929637C (en) | USE OF IL-22 DIMERS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF PANCREATITIS | |
| CN102711733A (zh) | 瞬时连接于聚合物载体的干生长激素组合物 | |
| CN107787328B (zh) | 用于治疗血友病的截短的血管性血友病因子多肽 | |
| US20220287347A1 (en) | Peptides for treating muscle atrophy | |
| KR20170026580A (ko) | 변형된 폰 빌레브란트 인자 | |
| ES2912300T3 (es) | Procedimientos de preparación de factor von Willebrand modificado | |
| JP2004536056A (ja) | Ｒａｎｋアンタゴニストの療法使用 | |
| ES2869339T3 (es) | Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia |